Acadian Asset Management
SLN

Acadian Asset Management’s Silence Therapeutics SLN Stock Holding History

Acadian Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25K Buy
+4,818
New +$26.5K ﹤0.01% 1931
2025
Q4 		– Sell
-4,218
Closed -$21K – 2110
2025
Q3 		$21K Buy
+4,218
New +$23.4K ﹤0.01% 1768
2025
Q2 		– Sell
-12,153
Closed -$34K – 1815
2025
Q1 		$34K Sell
12,153
-7,314
-38% -$35.7K ﹤0.01% 1483
2024
Q4 		$133K Buy
+19,467
New +$251K ﹤0.01% 1320

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Acadian Asset Management's SLN Position: Q1 2026 in Review

Acadian Asset Management opened a new position in Silence Therapeutics (SLN) in Q1 2026: 4,818 shares worth $25K. The stake represents ﹤0.01% of the portfolio and ranks #1931 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in SLN as recently as Q3 2025.

Acadian Asset Management first reported a position in SLN in Q4 2024 and has held it in 4 quarters since. The position peaked at $133K in Q4 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Acadian Asset Management held 4,818 shares of Silence Therapeutics worth $25K as of Q1 2026.
  • Silence Therapeutics was a new Acadian Asset Management position in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1931 holding.
  • Acadian Asset Management first reported a position in Silence Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Acadian Asset Management's Silence Therapeutics position peaked at $133K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.